The focus of cancer burden research is on comprehensive assessment and prediction of the population burden caused by cancer.
Cancer burden is examined in different population groups, such as by socioeconomic status, ethnic background and region.
The study aims to assess the impacts of the Covid-19 pandemic on cancer in the Nordic countries. First, the impact of the pandemic on reporting activity and incidence was assessed. Currently, excess mortality and other more clinical endpoints are being examined. Excess mortality analyses are performed in the registry.
The increase in cancer incidence and improved patient survival rates result in an increasing number of people who have had cancer. Thus, the risk of new cancer in patients is also a growing challenge. The risk of a second cancer may be related to the treatment of the first cancer, or it may be due to the same lifestyle factors as the first cancer. In addition, genetic predisposition plays a role in certain known cases. The study aims to investigate the incidence of second cancers in adult cancer patients.
This research is part of the Center of Excellence in Tumor Genetics Research led by Professor Lauri Aaltonen. The study investigates, among other things, the connection between cancer and comorbidities and seeks possible patient populations with hereditary cancer susceptibility. The research aims to identify molecular genetic changes based on hereditary or observed susceptibility factors.
Project website: https://www.helsinki.fi/en/researchgroups/finnish-center-of-excellence-in-tumor-genetics-research
The purpose of the study is to investigate how surgical interventions in benign gynaecological diseases have varied over time and what effects this has had on the incidence and incidence estimates of uterine cancer, especially endometrial and ovarian cancer, and fallopian tube cancers. Practices regarding hysterectomies, oophorectomies, and salpingectomies have changed over time, which can affect over- or underestimation of cancer incidence.